atDose key facts
as of Oct 2026- Developer of a mobile dosing and infusion device designed to change the treatment methods for serious illnesses.
- atDose is valued at approximately $36.9M as of Oct 2026 (last reported valuation).
- It has raised $4.1M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Japan External Trade Organization, FASTAR, DEFTA Partners, J-StarX.
- Status: Privately Held (backing).
atDose's last reported valuation, Dec 2024. Nothing priced has surfaced since.
- ·Watch atDose: the Monday email on marks, rounds and moves
atDose funding rounds
No funding rounds for atDose are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs atDose
4atDose valuation
atDose's last reported valuation was $36.9 million in Dec 2024. No priced round, secondary trade or fund mark has surfaced since.
atDose investors
4 investors are on record for atDose, including Japan External Trade Organization, FASTAR, DEFTA Partners and J-StarX.
About atDose
Developer of a mobile dosing and infusion device designed to change the treatment methods for serious illnesses. The company's device directly administers the drug to the affected area by combining a microneedle and an electroosmotic flow pump as used in acupuncture and moxibustion treatment, enabling cancer patients to reduce their physical burden, which is caused by the side effects of drugs.
- Sector
- Healthcare
- HQ
- Yokohama, Japan
- Founded
- 2017
- Employees
- 3
- Website
- atdose.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.